“While great progress has been made in recent years in the development of public health within the European Union (EU), the Covid-19 pandemic brought to light existing vulnerabilities in the European health response mechanism, from Member State incoordination to difficulties in manufacturing and accessing medicines, to EU research fragmentation and differences between corporate R&D choices and public health priorities.”

Click here to know more and to register to the event.

Click here to visualize the program.

Click here to read the participants’ booklet.

Some useful reading:

• Do we need a public European medicines infrastructure? – EPRS
• Interview with Massimo Florio about a new European approach to pharmaceutical policy – European Science-Media Hub
  
• Article in La Stampa, 13/07/2022, Florio and Barca
• Study prepared at request of the Panel for the Future of Science and Technology STOA (Click here for the Presentation of the study, click here for the webstream)